CIK 0000875320 · Large accelerated filer
VERTEX PHARMACEUTICALS INC / MA
Sign in to watch- Ticker
- VRTX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- MA
- Entity type
- operating
- EIN
- 043039129
- Phone
- 6173416393
- Business address
- 50 NORTHERN AVENUE, BOSTON, MA, 02210
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $6,307,135
- in 1 filing, $6.3M under 10b5-1 plans
Net −$6,307,135. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-02-13 | Biller Jonathan EVP and Chief Legal Officer | Shares withheld for taxes 10b5-1 | −2,993 | $487.76 | $1.5M | 17,826 |
| 2026-02-13 | Biller Jonathan EVP and Chief Legal Officer | Sale 10b5-1 | −988 | $499.00 | $493K | 16,838 |
| 2026-02-13 | Bhatia Sangeeta N. Director | Sale 10b5-1 | −266 | $500.00 | $133K | 4,299 |
| 2026-02-13 | Atkinson Edward Morrow III EVP, Chief Technical Ops. Off. | Shares withheld for taxes | −1,903 | $487.76 | $928K | 20,143 |
| 2026-02-13 | Ambrose Kristen SVP & Chief Accounting Officer | Shares withheld for taxes | −1,393 | $487.76 | $679K | 8,734 |
| 2026-02-11 | Tatsis Ourania EVP, Chief Reg. & Quality Off. | Sale 10b5-1 | −466 | $460.43 | $215K | 51,436 |
| 2026-02-11 | Bunnage Mark E. EVP, Chief Scientific Officer | Sale 10b5-1 | −2,021 | $460.43 | $931K | 12,914 |
| 2026-02-11 | Biller Jonathan EVP and Chief Legal Officer | Sale 10b5-1 | −1,925 | $460.43 | $886K | 20,819 |
| 2026-02-11 | Atkinson Edward Morrow III EVP, Chief Technical Ops. Off. | Sale 10b5-1 | −1,751 | $460.43 | $806K | 22,046 |
| 2026-02-11 | Ambrose Kristen SVP & Chief Accounting Officer | Sale 10b5-1 | −1,376 | $460.43 | $634K | 10,127 |
| 2026-02-10 | WAGNER CHARLES F JR EVP, CO & FO | Shares withheld for taxes | −3,045 | $468.41 | $1.4M | 48,280 |
| 2026-02-10 | Tatsis Ourania EVP, Chief Reg. & Quality Off. | Shares withheld for taxes 10b5-1 | −2,140 | $468.41 | $1.0M | 51,902 |
| 2026-02-10 | Sachdev Amit EVP Chief Patient & Ext Af Off | Shares withheld for taxes | −2,057 | $468.41 | $964K | 68,941 |
| 2026-02-10 | McKechnie Duncan EVP, Chief Commercial Officer | Shares withheld for taxes | −1,127 | $468.41 | $528K | 21,811 |
| 2026-02-10 | Kewalramani Reshma CEO & President | Shares withheld for taxes | −8,297 | $468.41 | $3.9M | 146,528 |
| 2026-02-10 | Bunnage Mark E. EVP, Chief Scientific Officer | Shares withheld for taxes 10b5-1 | −1,127 | $468.41 | $528K | 14,935 |
| 2026-02-10 | Bozic Carmen EVP and CMO | Shares withheld for taxes | −2,145 | $468.41 | $1.0M | 41,857 |
| 2026-02-10 | Biller Jonathan EVP and Chief Legal Officer | Shares withheld for taxes 10b5-1 | −1,630 | $468.41 | $764K | 22,744 |
| 2026-02-10 | Atkinson Edward Morrow III EVP, Chief Technical Ops. Off. | Shares withheld for taxes 10b5-1 | −872 | $468.41 | $408K | 23,797 |
| 2026-02-10 | Ambrose Kristen SVP & Chief Accounting Officer | Shares withheld for taxes 10b5-1 | −592 | $468.41 | $277K | 11,503 |
Page 8 of 10 · 182 trades